Status:

TERMINATED

Study to Evaluate the Effects of ONO-2952 on Pain Perception Produced by Rectal Distention in Female Subjects With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D)

Lead Sponsor:

Ono Pharma USA Inc

Conditions:

Irritable Bowel Syndrome (IBS)

Eligibility:

FEMALE

18-65 years

Phase:

PHASE2

Brief Summary

The objective is to evaluate whether ONO-2952 modulates visceral pain perception produced by rectal distention in female patients with IBS-D

Eligibility Criteria

Inclusion

  • Female 18-65 years of age (inclusive)
  • Diagnosed with IBS based on the following criteria (Rome III criteria):
  • Symptom onset at least 6 months prior to diagnosis, and
  • Recurrent abdominal pain or discomfort at least 3 days per month for the past 3 months, and
  • Abdominal discomfort or pain associated with two or more of the following at least 25% of the time:
  • improvement with defecation
  • onset associated with a change in frequency of stool/defecation
  • onset associated with a change in form (appearance) of stool
  • Diagnosed with IBS-D, defined as loose/watery stools ≥ 25% and hard/lumpy stools ≤ 25% of defecations

Exclusion

  • Any structural abnormality of the gastrointestinal (GI) tract (other than esophagitis or gastritis)
  • History of Chron's disease, ulcerative colitis, diabetes mellitus, lactose malabsorption, malabsorption syndromes, celiac sprue, or any upper GI symptoms that may impact the assessment of IBS symptoms

Key Trial Info

Start Date :

June 1 2013

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

Estimated Enrollment :

39 Patients enrolled

Trial Details

Trial ID

NCT01887002

Start Date

June 1 2013

Last Update

February 25 2016

Active Locations (4)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (4 locations)

1

Boston Clinical Site

Boston, Massachusetts, United States, 02215

2

St. Louis Clinical Site

St Louis, Missouri, United States, 63110

3

Chapel Hill Clinical Site

Chapel Hill, North Carolina, United States, 27599

4

Oklahoma City Clinical Site

Oklahoma City, Oklahoma, United States, 73160